SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Renewed strength across biotech, with IBB trading near record levels, is driving attention; traders point to sector rotation and resilient large-cap pharma, while noting that smaller biotech stocks have been less consistent and the rallys durability is uncertain.

Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More 

Equity

Geode’s largest ownership stake was in Sellas at 3%, followed by Iovance at 2% and ImmunityBio at 1%.

VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets

All 28 Solstice patients completing 96 weeks had undetectable virus.

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage 

Hims & Hers will report results on Monday after its Lilly agreement expanded access to Zepbound and Foundayo.

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas 

Prospera increased its stake nearly 70%, while Eversource trimmed its position 42% and Nemes Rush held steady.

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist 

Founder Patrick Soon-Shiong renewed his “NantX coming soon” teaser after the Binance theft, spotlighting his separate financial-services venture.

SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400% 

Kestra raised its stake by 256% and Principal Financial by 61%, while Commonwealth and Cambridge trimmed holdings.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

Capricor is recruiting two commercial bosses, with both listings for the preparations for a potential Deramiocel launch.

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

iShares Trust - iShares Biotechnology ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Geode added 1.2 million shares across the trio, with ImmunityBio seeing its largest increase.</li><li>LPL increased Sellas and ImmunityBio holdings while trimming Iovance. Russell expanded its Iovance position nearly 166%.</li><li>Stocktwits sentiment was ‘bullish’ for SLS and IOVA and ‘bearish’ for IBRX, while all three attracted more watchers over the past year.</li></ul><p>Barclays and Deutsche Bank disclosed holdings in Sellas Life Sciences (SLS), ImmunityBio (IBRX) and Iovance Biotherapeutics (IOVA), while Geode Capital Management added a combined 1.2 million shares across the three cancer-focused biotechs.</p><h2 class="st-heading-2"><strong>Barclays And Deutsche Bank Reveal Stakes</strong></h2><p>Barclays held its largest share position among the three in Iovance, owning about 0.11% of the company. Deutsche Bank held the most shares in&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a>, but its biggest ownership stake was in&nbsp;<a href="https://stocktwits.com/symbol/SLS">Sellas</a> at 0.1%, according to data tracked by Fiscal AI.&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Investor</td><td>SLS shares</td><td>IBRX shares</td><td>IOVA shares</td></tr><tr><td>Barclays</td><td>88,866</td><td>168,791</td><td>523,545</td></tr><tr><td>Deutsche Bank</td><td>197,537</td><td>445,777</td><td>416,904</td></tr><tr><td>Geode</td><td>5.2 million</td><td>10.6 million</td><td>10.5 million</td></tr></tbody></table></figure></div><p>Holdings disclosed on Friday showed that Deutsche Bank owned more than twice as many Sellas and ImmunityBio shares as Barclays as of Sept. 30, while Barclays held more&nbsp;<a href="https://stocktwits.com/symbol/IOVA">Iovance shares</a>.&nbsp;</p><h2 class="st-heading-2"><strong>Geode Adds More Across All 3 Stocks</strong></h2><p>Geode increased its holdings in all three, led by ImmunityBio. It added 758,758 shares, boosting that position 7.7% to 10.61 million, its largest increase by both share count and percentage.</p><p>It also added 287,644 Sellas shares, raising its holding 5.89% to 5.2 million, and 127,416 Iovance shares, lifting the position 1.2% to 10.45 million. Geode held 26.2 million shares across the three companies. Its largest ownership stake was in Sellas at 2.6%, followed by Iovance at 2.3% and ImmunityBio at 1%.</p><h2 class="st-heading-2"><strong>Other Investors Pick Different Favorites</strong></h2><p>Other investors include LPL Financial, Russell Investments, and Clearwater Capital Advisors&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Investor</td><td>SLS shares</td><td>IBRX shares</td><td>IOVA shares</td></tr><tr><td>LPL Financial</td><td>277,075</td><td>1,178,709</td><td>593,357</td></tr><tr><td>Russell Investments</td><td>71,138</td><td>191,298</td><td>513,032</td></tr></tbody></table></figure></div><p>LPL added to Sellas and ImmunityBio, while trimming Iovance. It increased its Sellas holding 78%, adding 121,412 shares, and its ImmunityBio position 15%, adding 157,652 shares. Its Iovance holding fell 10%, down 67,718 shares.</p><p>Russell’s largest percentage increase was in Iovance, where it added 319,979 shares to expand its position 165.75%. It also added 75,731 ImmunityBio shares, lifting that holding 65.33%, while trimming Sellas by just 87 shares. Meanwhile, Clearwater held 717,524 ImmunityBio shares and 21,711 Iovance shares.</p><h2 class="st-heading-2"><strong>Catalysts Behind The Cancer Stocks</strong></h2><p>Sellas expects results this quarter from its Phase 3 Regal trial of cancer immunotherapy Galinpepimut-S. The study reached the required 80th death last month, triggering its final analysis.</p><p>Sellas will also present Phase 2 SLS009 combination data at December’s American Society of Hematology (ASH) meeting. At the selected dose, response rates reached 54% in monocytic acute myeloid leukemia (AML) and 57% in patients with TP53 mutations after Venetoclax treatment failed.&nbsp;</p><p>ImmunityBio is focused on reaching more patients. The company said last week that the first patients in Germany and Austria had received Anktiva plus bladder-cancer immunotherapy BCG after their disease failed to respond to BCG alone. The rollout follows conditional European authorization in February, with Accord Healthcare supporting commercialization and Uniphar providing supply-chain services.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-first-patients-europe-treated-anktivar?utm_source=chatgpt.com">&nbsp;</a></p><p>Iovance, meanwhile, is turning growing demand into record revenue. Third-quarter sales hit $122 million, up about 80% from a year earlier, keeping the company on track for its 2026 revenue forecast of $410 million to $420 million.</p><p>Its next growth opportunity includes lung cancer. A Lifileucel study reported a 24.6% response rate in 69 patients, including two unconfirmed responses, and 59.1% in a subgroup selected using biological markers. Iovance plans a supplemental FDA application for the indication in 2027.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About SLS, IBRX And IOVA?</strong></h2><p>On Stocktwits, SLS and IOVA drew ‘bullish’ sentiment, with ‘normal’ message volume for SLS and ‘high’ activity for IOVA. IBRX sentiment was ‘bearish’ amid ‘low’ message volume. All three have attracted more watchers over the past year. IBRX led with a 63% increase in its watcher base, followed by SLS at 34% and IOVA at 24%.</p><p>One user&nbsp;<a href="https://stocktwits.com/Juhanialainen/message/668541426">said</a> of Sellas, “I’m holding, buying just a little, not selling.” Another user&nbsp;<a href="https://stocktwits.com/wwwgill1/message/668537170">said</a> of ImmunityBio, “We're overdue for a good time!”</p><p><stembedurl>https://stocktwits.com/Juhanialainen/message/668541426</stembedurl></p><p>A separate user&nbsp;<a href="https://stocktwits.com/Badgerkid/message/668533783">said</a> of Iovance, “Fundamentals typically do win out in the end, but time is part of that equation.” The user favored holding for the long term and speculated that a potential buyer would need to pay $20 billion to $40 billion.</p><p><stembedurl>https://stocktwits.com/Badgerkid/message/668533783</stembedurl></p><p>IBRX leads the trio with a 336% year-to-date gain, followed by IOVA at 195% and SLS at 123%. All three have far outpaced sector benchmarks: the iShares Biotechnology ETF (IBB), up 27%, the SPDR S&amp;P Biotech ETF (XBI), up 25%, and the Health Care Select Sector SPDR ETF (XLV), up 21%.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-cybertruck-makes-way-cybercab-terafab-1m-wafers-monthly/cNGr2CAR9eg">TSLA Stock Slips Overnight As Cybertruck Makes Way For Cybercab — Terafab Reportedly Eyes 1M Wafers Monthly&nbsp;</a></p>

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Current Price	$219.92
Prev Close	$213.63
Open	$214.89
Dividend Yield	N/A
50-Day Moving Average	$208.46
Beta	N/A
Avg. Volume	1.83M
PE Ratio	N/A

52-Week High	$222.29
52-Week Low	$158.37
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IBB Fundamentals